Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from ...

Guardant's precision oncology tests are now available to the hundreds of providers who rely on the Halo Intelligence platform for real-time oncology insights nationwide.

New integration brings Guardant Health's complete oncology testing portfolio into the VieCure Halo Intelligence platform, streamlining access to precision diagnostics at the point of care DENVER ...

Cathie Wood’s ARK ETFs have released their daily trade report for Tuesday, 22 July 2025, showcasing a series of strategic buy ...

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many ...

Guardant Health’s first quarter results were shaped by strong growth in both its oncology and screening businesses, with management crediting product upgrades and increasing test volumes as key ...

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025.